Greater Cumulative Benefits from Ixekizumab versus Ustekinumab Treatment over 52 Weeks for Patients with Moderate-to-Severe Psoriasis in a Randomized, Double-Blinded Phase 3b Clinical Trial.

CONCLUSIONS: IXE showed greater cumulative clinical benefit than UST. PMID: 30799638 [PubMed - as supplied by publisher]
Source: Journal of Dermatological Treatment - Category: Dermatology Tags: J Dermatolog Treat Source Type: research